Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Femasys ( (FEMY) ).
On November 3, 2025, Femasys Inc. announced it has received FDA approval to advance the final phase of the FemBloc trial, a non-surgical permanent birth control method, marking a significant step towards potential U.S. market entry. Additionally, Femasys secured $12 million in financing, with potential to reach $58 million, which will be used to refinance existing debt and support the commercialization of its fertility and birth control portfolio, reflecting strong investor confidence in the company’s mission to transform women’s health.
The most recent analyst rating on (FEMY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
Spark’s Take on FEMY Stock
According to Spark, TipRanks’ AI Analyst, FEMY is a Neutral.
Femasys’ overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and cash flow challenges. Technical analysis provides some short-term positive signals, but the long-term outlook remains uncertain. Valuation metrics are unfavorable due to negative earnings and lack of dividends, further weighing down the score.
To see Spark’s full report on FEMY stock, click here.
More about Femasys
Femasys Inc. is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide. The company offers a range of novel, in-office therapeutic and diagnostic products, including the FemBloc non-surgical permanent birth control and FemaSeed intratubal insemination, which have received regulatory approvals in various international markets.
Average Trading Volume: 5,670,018
Technical Sentiment Signal: Sell
Current Market Cap: $27.4M
For an in-depth examination of FEMY stock, go to TipRanks’ Overview page.